Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Trial

The push signals a final call for investors to shape the case’s leadership as the lawsuit moves forward.

Overview

Two shareholder firms, Schall and DJS, reminded Nektar investors of a pending lead‑plaintiff deadline and invited eligible shareholders to come forward.
The class action alleges violations of federal securities laws under Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5.
The filings claim Nektar failed to follow enrollment protocol in the REZOLVE‑AA Phase 2b study of rezpegaldesleukin, which was likely to harm the trial’s results.
Plaintiffs say the company overstated the study’s integrity and issued misleading statements during 2025, which they argue led to investor losses when problems surfaced.
The class has not been certified yet, and investors may seek appointment as lead plaintiff, though that step is not required to take part in any recovery.